Novo Nordisk
kr 250.00Change from previous close: −1.26%Absolute change: −kr 3.20
Valuation
Data as of October 3, 2026
Valuation multiples
- Market cap
- kr 1.1T
- Enterprise value
- kr 1.2T
- P/E (trailing 12 months)
- 9.47
- Forward P/E
- 11.4
- PEG
- 4.34
- Price/book
- 4.98
- Price/sales
- 3.33
- EV/EBITDA
- 6.89
- EV/revenue
- 3.63
Profitability and growth
- Gross margin
- 82.0%
- Operating margin
- 42.5%
- Net margin
- 35.3%
- ROE
- 59.8%
- ROA
- 18.7%
- Revenue growth (year over year)
- 2.1%
- Earnings growth (year over year)
- -20.6%
Financial health
- Total cash
- kr 44.98B
- Total debt
- kr 140.13B
- Debt/equity
- 0.63
- Current ratio
- 0.87
- Quick ratio
- 0.64
Dividends
- Annual dividend per share
- kr 11.70
- Dividend yield
- 4.7%
- Payout ratio
- 44.6%
- Ex-dividend date
- August 14, 2026
Analysts and estimates
- Average price target
- kr 307.34
- Median price target
- kr 300.00
- High price target
- kr 452.00
- Low price target
- kr 203.00
- Analysts with a price target
- 23
- Consensus
- Hold
- Forward EPS
- kr 21.86
- EPS estimate, current year
- kr 21.64
Shares and trading
- Beta
- 0.34
- Average volume
- 4.53M
- Shares outstanding
- 3.34B
- Float
- 3.17B
- Institutional ownership
- 33.2%
- Insider ownership
- 5.3%